FDA approves first therapy for high-risk neuroblastoma
The U.S. Food and Drug Administration today approved Unituxin (dinutuximab) as part of first-line therapy for pediatric patients with high-risk neuroblastoma, a type of cancer that most often occurs in young children.
Source: Food and Drug Administration - Category: American Health Source Type: news
More News: American Health | Cancer | Cancer & Oncology | Children | Food and Drug Administration (FDA) | Neuroblastoma | Neurology | Pediatrics